• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Harrison Miles converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

    5/23/25 4:10:47 PM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Harrison Miles

    (Last) (First) (Middle)
    C/O CASTLE BIOSCIENCES, INC.
    505 S. FRIENDSWOOD DRIVE, SUITE 401

    (Street)
    FRIENDSWOOD TX 77546

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CASTLE BIOSCIENCES INC [ CSTL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/21/2025 M 8,673 A (1) 21,964 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 05/21/2025 M 8,673 (2) (2) Common Stock 8,673 $0 0 D
    Restricted Stock Units (1) 05/22/2025 A 13,667 (3) (3) Common Stock 13,667 $0 13,667 D
    Explanation of Responses:
    1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
    2. The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 23, 2025, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
    3. The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
    Remarks:
    /s/ Frank Stokes, Attorney-in-fact 05/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CSTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Castle Biosciences with a new price target

      Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

      12/14/23 6:54:55 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Castle Biosciences with a new price target

      Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

      1/5/23 7:53:37 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Stephens & Co. initiated coverage on Castle Biosciences with a new price target

      Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

      1/7/22 5:42:05 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    SEC Filings

    See more
    • Castle Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

      5/23/25 4:39:01 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

      SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      5/12/25 3:55:49 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Castle Biosciences Inc.

      10-Q - CASTLE BIOSCIENCES INC (0001447362) (Filer)

      5/5/25 4:10:32 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

      FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB ("SciBase") utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis (AD). "We have been successful in developing several tests that enable clinicians to improve treatment plan decisions for their pati

      6/16/25 4:30:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

      FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will explore the challenges precision medicine companies face in commercializing innovative diagnostic tests and discuss strategies for navigating today's market complexities while remaining focused on improving care for patients. Panel Details:Ti

      6/11/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

      Gold-level Stevie® Award recognizes Maetzold's transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Business Products Industries category in the 23rd Annual American Business Awards. The American Business Awards recognizes outstanding business performances in the United States. Also known as The Stev

      6/4/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cole G Bradley converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 5:01:17 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Bradbury Daniel converted options into 8,673 shares (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 4:19:15 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Director Cotton Rodney converted options into 8,673 shares, increasing direct ownership by 163% to 14,002 units (SEC Form 4)

      4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

      5/23/25 4:17:29 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

      The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

      4/30/24 4:30:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

      SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

      5/26/21 12:42:00 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/14/24 4:40:39 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      11/13/24 6:44:33 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

      SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

      7/8/24 4:32:39 PM ET
      $CSTL
      Medical Specialities
      Health Care

    $CSTL
    Financials

    Live finance-specific insights

    See more
    • Castle Biosciences Reports First Quarter 2025 Results

      Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum

      5/5/25 4:06:00 PM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

      FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

      4/14/25 7:00:00 AM ET
      $CSTL
      Medical Specialities
      Health Care
    • Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

      Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared to 2023 Anticipate generating between $280-295 million in total revenue in 2025 Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended December 31, 2024. "Castle delivered an outst

      2/27/25 4:05:00 PM ET
      $CSTL
      Medical Specialities
      Health Care